Form 4: Lantern Pharma CSO Granted 10,000 Stock Options

Lantern Pharma's Chief Scientific Officer, Kishor G. Bhatia, was granted 10,000 stock options with an exercise price of $3.24 per share.

Summary

• Kishor G. Bhatia, Chief Scientific Officer of Lantern Pharma Inc. (LTRN), was granted 10,000 stock options.
• The options have an exercise price of $3.24 per share.
• The grant date for these options was December 18, 2025.
• The options will expire on December 17, 2035.
• Vesting occurs in equal monthly increments over a 24-month period, starting January 18, 2026.
• The options were granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options is a routine compensation event that aligns executive interests with shareholders, but it doesn't inherently signal new positive or negative operational news. The future vesting schedule provides a positive long-term incentive.

Positives

• The grant of stock options aligns the interests of the Chief Scientific Officer with those of shareholders, incentivizing long-term company performance.
• The options are granted under an existing, approved stock incentive plan, indicating a structured approach to executive compensation.

Negatives

• The exercise price of $3.24 per share means the stock price must rise above this level for the options to have intrinsic value, representing a potential dilution if exercised in the future.

Future Outlook

The vesting schedule extending to January 2028 indicates a long-term incentive for the Chief Scientific Officer, aligning their future performance with the company's growth over the next two years.

Industry Context

Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, aiming to attract and retain key scientific talent and align their interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of 10,000 stock options to a Chief Scientific Officer is a common practice in the biotech sector for executive retention and motivation.
• A 24-month vesting period is typical for such grants, often seen in companies like Moderna or BioNTech for key personnel, ensuring continued commitment.
• The 10-year expiration date (from grant) is also standard for employee stock options, providing a long window for value realization.

Related Party Transactions

• Grant of stock options to Kishor G. Bhatia, Chief Scientific Officer, as part of his compensation package under the company's approved stock incentive plan.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also potential for increased executive motivation leading to long-term value creation.
• Employees: May signal stability in executive leadership and a commitment to long-term incentives.

Next Steps

• The stock options will begin vesting in equal monthly increments starting January 18, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine stock option grant to a key executive, which is a standard compensation practice. It does not provide new information that would fundamentally alter the investment thesis for Lantern Pharma, hence a 'hold' recommendation is appropriate as it doesn't present a strong buy or sell signal based solely on this filing.

Keywords

Lantern Pharma, LTRN, Stock Options, Kishor G. Bhatia, Chief Scientific Officer, Executive Compensation, SEC Form 4, Beneficial Ownership, Equity Grant